Antineoplastic agents. 465. Structural modification of resveratrol

Sodium resverastatin phosphate

George Pettit, Matthew P. Grealish, M. Katherine Jung, Ernest Hamel, Robin Pettit, Jean Chapuis, Jean M. Schmidt

Research output: Contribution to journalArticle

153 Citations (Scopus)

Abstract

As an extension of structure/activity investigations of resveratrol (1), phenstatin (2c), and the cancer antiangiogenesis drug sodium combretastatin A-4 phosphate (2b), syntheses of certain related stilbenes (14) and benzophenones (16) were undertaken. The trimethyl ether derivative of (Z)-resveratrol (4a) exhibited the strongest activity (GI50 = 0.01-0.001 μg/mL) against a minipanel of human cancer cell lines. A monodemethylated derivative (14c) was converted to prodrug 14n (sodium resverastatin phosphate) for further biological evaluation. The antitubulin and antimicrobial activities of selected compounds were also evaluated.

Original languageEnglish (US)
Pages (from-to)2534-2542
Number of pages9
JournalJournal of Medicinal Chemistry
Volume45
Issue number12
DOIs
StatePublished - Jun 6 2002

Fingerprint

Antineoplastic Agents
Benzophenones
Derivatives
Stilbenes
Prodrugs
Ether
Neoplasms
Sodium
Phosphates
Cells
Cell Line
Pharmaceutical Preparations
sodium phosphate
resveratrol
fosbretabulin

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Antineoplastic agents. 465. Structural modification of resveratrol : Sodium resverastatin phosphate. / Pettit, George; Grealish, Matthew P.; Jung, M. Katherine; Hamel, Ernest; Pettit, Robin; Chapuis, Jean; Schmidt, Jean M.

In: Journal of Medicinal Chemistry, Vol. 45, No. 12, 06.06.2002, p. 2534-2542.

Research output: Contribution to journalArticle

Pettit, George ; Grealish, Matthew P. ; Jung, M. Katherine ; Hamel, Ernest ; Pettit, Robin ; Chapuis, Jean ; Schmidt, Jean M. / Antineoplastic agents. 465. Structural modification of resveratrol : Sodium resverastatin phosphate. In: Journal of Medicinal Chemistry. 2002 ; Vol. 45, No. 12. pp. 2534-2542.
@article{b3a39858b5324e029d45453a1d215151,
title = "Antineoplastic agents. 465. Structural modification of resveratrol: Sodium resverastatin phosphate",
abstract = "As an extension of structure/activity investigations of resveratrol (1), phenstatin (2c), and the cancer antiangiogenesis drug sodium combretastatin A-4 phosphate (2b), syntheses of certain related stilbenes (14) and benzophenones (16) were undertaken. The trimethyl ether derivative of (Z)-resveratrol (4a) exhibited the strongest activity (GI50 = 0.01-0.001 μg/mL) against a minipanel of human cancer cell lines. A monodemethylated derivative (14c) was converted to prodrug 14n (sodium resverastatin phosphate) for further biological evaluation. The antitubulin and antimicrobial activities of selected compounds were also evaluated.",
author = "George Pettit and Grealish, {Matthew P.} and Jung, {M. Katherine} and Ernest Hamel and Robin Pettit and Jean Chapuis and Schmidt, {Jean M.}",
year = "2002",
month = "6",
day = "6",
doi = "10.1021/jm010119y",
language = "English (US)",
volume = "45",
pages = "2534--2542",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "12",

}

TY - JOUR

T1 - Antineoplastic agents. 465. Structural modification of resveratrol

T2 - Sodium resverastatin phosphate

AU - Pettit, George

AU - Grealish, Matthew P.

AU - Jung, M. Katherine

AU - Hamel, Ernest

AU - Pettit, Robin

AU - Chapuis, Jean

AU - Schmidt, Jean M.

PY - 2002/6/6

Y1 - 2002/6/6

N2 - As an extension of structure/activity investigations of resveratrol (1), phenstatin (2c), and the cancer antiangiogenesis drug sodium combretastatin A-4 phosphate (2b), syntheses of certain related stilbenes (14) and benzophenones (16) were undertaken. The trimethyl ether derivative of (Z)-resveratrol (4a) exhibited the strongest activity (GI50 = 0.01-0.001 μg/mL) against a minipanel of human cancer cell lines. A monodemethylated derivative (14c) was converted to prodrug 14n (sodium resverastatin phosphate) for further biological evaluation. The antitubulin and antimicrobial activities of selected compounds were also evaluated.

AB - As an extension of structure/activity investigations of resveratrol (1), phenstatin (2c), and the cancer antiangiogenesis drug sodium combretastatin A-4 phosphate (2b), syntheses of certain related stilbenes (14) and benzophenones (16) were undertaken. The trimethyl ether derivative of (Z)-resveratrol (4a) exhibited the strongest activity (GI50 = 0.01-0.001 μg/mL) against a minipanel of human cancer cell lines. A monodemethylated derivative (14c) was converted to prodrug 14n (sodium resverastatin phosphate) for further biological evaluation. The antitubulin and antimicrobial activities of selected compounds were also evaluated.

UR - http://www.scopus.com/inward/record.url?scp=0037030688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037030688&partnerID=8YFLogxK

U2 - 10.1021/jm010119y

DO - 10.1021/jm010119y

M3 - Article

VL - 45

SP - 2534

EP - 2542

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 12

ER -